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Abstract
Background: Dexamethasone (DEX) has been routinely used as a pre-treatment in the clinical application of
paclitaxel (PTX) to treat ovarian cancer. However, PTX-induced apoptosis might be inhibited by DEX. This study was
undertaken to investigate the effects of DEX on the apoptosis induced by PTX.
Methods: Both of SKOV-3 and HO-8910 human ovarian cancer cells were divided into four groups: (1) untreated
(Con); (2) treated with DEX (0.1 μM) alone; (3) treated with PTX (50 nM); and (4) pre-treated with DEX (0.1 μM), and
24 h later, treated with PTX (DEX + PTX). Cell proliferation was determined by the 3-(4,5)-dimethylthiahiazo
(−z-y1)-3,5-di- phenytetrazoliumromide (MTT) dye uptake method, while cell apoptosis was analyzed by propidium
iodide (PI) staining and flow cytometry. Then, reverse transcription polymerase chain reactions (RT-PCRs) were
applied to semi-quantitative analysis, followed by western blot analysis. Statistical analysis was performed, with
Fisher’s least significant difference test.
Results: Our results demonstrated that DEX can differentially inhibit SKOV-3 and HO-8910 cell proliferation induced
by PTX and decrease the apoptosis rates in cancer cells. Pre-treatment with DEX could up-regulate the expressions
of members of anti-apoptotic Bcl-2 family (Bcl-2 and Bcl-XL) and members of IAP family (survivin). The expression of
cleaved caspase-3 was down-regulated by DEX, shown by semi-quantitative RT-PCRs and western blot analysis.
Conclusions: Our data gained invaluable insights of the antagonistic mechanisms of DEX on PTX-induced cancer
cell death and may provide new methods of using DEX as antineoplastic drugs or agents in the clinical treatment
for ovarian cancer patients.
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Introduction
Ovarian cancer has the poorest prognosis of all
gynecological cancers and is a leading cause of death in
women with cancers [1,2]. Recently, new chemotherapeu-
tic agents, including taxanes, gemcitabine and irinotecan,
have become clinically available to treat ovarian cancer.
Among these newer drugs, paclitaxel (PTX) is the one
used most frequently for the treatment of patients with
ovarian cancer, especially the advanced ovarian cancer.
The exact mechanism of cell death induced by PTX is
elusive, though it is widely known that the major cellular
target of PTX is the tubulin/microtubule system in mi-
tosis [3]. Dexamethasone (DEX) is routinely used as a
pre-treatment in the clinical application of PTX to pre-
vent hypersensitivity reactions and other adverse effects
such as nausea, emesis and toxic reactions [4-6].
However, recent studies have discovered that DEX
selectively inhibits PTX-induced apoptosis in a number
of carcinoma cell lines, including ovary, breast, testis,
prostate, bladder, pancreas, kidney, liver, colon, brain,
cervix, bone and skin [7-14]. The inhibition of PTX-
induced apoptosis by DEX may occur through enhancing
DNA repair capacity, suppressing host antitumor immune
responses or blocking apoptosis [15,16]. The apoptosis of
cancer cell may be antagonized by anti-apoptotic modula-
tor proteins, such as survivin (a member of the IAP family),
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Bcl-2 and Bcl-XL (members of the Bcl-2 family). The death
receptor and mitochondrial death pathways may be linked
by Bcl-XL, which subsequently activates the proteolytic ac-
tivation of effector caspases-3 to trigger the mitochondrial
dysfunction and cytochrome c release [17-19]. Also, DEX
pre-treatment has been recently reported to interfere with
apoptotic death in brain tumour cells by the transcriptional
activation of a Bcl-XL gene [20-26].
To determine whether DEX would inhibit PTX-induced
apoptosis in ovarian cancer cells and reduce the therapeutic
efficacy of PTX, we performed in vitro experiments with
the human ovarian cancer SKOV-3 and HO-8910 cell lines
to evaluate the effects and mechanisms of DEX on human
ovarian cancer cell apoptosis induced by PTX. Surprisingly,
DEX had a strong anti-apoptotic effect on the carcinoma
cells and prevented PTX-induced cancer cell reduction and
apoptosis. This result was due to the inhibition of key mole-
cules of death receptor and mitochondrial apoptosis path-
way, resulting in a blockade of caspase activity. The direct
transfer of caspases restored the apoptosis sensitivity of
DEX-treated carcinomas in vitro. These findings suggest
that the pro-apoptotic effects of chemotherapy regimens in
patients with ovarian cancer might be strongly antagonized
by the anti-apoptotic effects of DEX.
Materials and methods
Cell culture and group
SKOV-3 and HO-8910 human ovarian cancer cells were
obtained from Shanghai Cancer Institute, and cultured in
RPMI-1640 (Invitrogen, Carlsbad, CA) supplemented with
10% fetal bovine serum (Sigma Chemical Co., St. Louis,
MO) and 1% penicillin and streptomycin (Sigma Chemical
Co., St. Louis, MO) in a 5% CO2 and 37°C incubator. DEX
(Sigma Chemical Co., St. Louis, MO) was dissolved in
ethanol before added to culture medium. The final ethanol
concentration was 0.1%. PTX (Sigma Chemical Co., St.
Louis, MO) was dissolved in PBS (PH 7.4, Sigma Chemical
Co., St. Louis, MO) with a concentration of 1 μM.
The SKOV-3 and HO-8910 cells were divided into
four groups: (1) untreated (Con); (2) treated with DEX
(0.1 μM) alone; (3) treated with PTX (50 nM); and (4)
pre-treated with DEX (0.1 μM), and 24 h later, treated
with PTX (DEX + PTX).
Cell proliferation assay
The proliferation of SKOV-3 and HO-8910 were determined
by the 3-(4,5)-dimethylthiahiazo (−z-y1)-3,5-di- phenytetra-
zoliumromide (MTT) dye uptake method. Briefly, cells
(10,000/well) were incubated in triplicate in a 96-well plate
in a final volume of 0.1 mL for the indicated time periods at
37°C. Then, 0.025 mL of MTT solution (5 mg/mL in PBS)
was added to each well. After 2 h incubation at 37°C, 0.1 mL
dimethylformamide (Sigma Chemical Co., St. Louis, MO)
was added, incubation was continued for 30 min at 37°C,
and then the O.D. value was measured using a Bio-Rad
(Model 550) microplate reader at 570 nm, take dimethylfor-
mamide as the blank.
Propidium Iodide (PI) staining by flow cytometry
Four groups of cells were harvested and centrifuged at
1,000 rpm for 5 min and then fixed in 5 mL 70% pre-
refrigerated ethanol for 24 h at −20°C. After washing
the cells with 10 μL PBS twice, 1 mg/mL RNase
(Sigma Chemical Co., St. Louis, MO) was added and
incubated for 30 min at 37°C. Then, cells were stained with
300 μL/50 μg/mL PI (Sigma Chemical Co., St. Louis, MO)
in the dark for 30 min at 4°C. Cell apoptosis was analyzed
by flow cytometry (FCM, FACScan, Becton, Dickinson and
Company, Franklin Lakes, NJ, USA).
Apoptosis assay
Four groups of cells were collected and washed twice
with PBS. Cells were centrifuged at 1,000 rpm for 5 min
and then were resuspended in reaction buffer (200 μL
HEPES (2-[4-(2-Hydroxyethyl)-1-piperazinyl] ethanesul-
fonic acid, Sigma Chemical Co., St. Louis, MO) buffer,
1 μL fluorescein isothiocyanate-labeled annexin V (annexin
V-FITC), 2 μL/50 μg/mL PI, ApoAlert Annexin V–FITC
Apoptosis Kit, CLONTECH) and incubated in dark for
10 min at room temperature. After 1 h, cell apoptosis was
analyzed by flow cytometry.
Semi-quantitative analysis
To semi-quantify the mRNAs of survivin, Bcl-2, and
Bcl-XL, reverse transcription polymerase chain reactions
(RT-PCRs) were performed. Cells were washed with ice-
cold PBS once, and total RNA was isolated with TRIzol
(Invitrogen Life Technologies, San Diego, CA), according
to the instructions of the manufacturer. Approximately
2 μg RNA was treated with ribonuclease-free deoxyribo-
nuclease, and cDNA was synthesized by using Moloney
murine leukemia virus reverse transcriptase (Invitrogen
Life Technologies, Carlsbad, CA), and 2 μL of synthesized
cDNA was subjected to 30 cycles of PCR that resulted in a
single specific amplification product of the expected size.
The PCR conditions were as follows: 30 sec denaturation
at 94°C, 1 min annealing at 55°C, and 45 sec extension
at 72°C. PCR primers used in this study were as follows:
survivin, sense 5′-TTGGCAGGTGCCTGTTGAAT-3′
and antisense 5′-AGCCAGTCCCCCACAGCAT-3′; Bcl-2,




Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as an internal control of the PCR. The primers for
GAPDH were sense 5′-GGATTTGGTCGTATTGGG-3′
and antisense 5′-GGAAGATGGTGATGGGATT-3′.
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To determine the specificity of RT-PCRs, we per-
formed the amplifications three times and took the
mean value of these three reactions. The RT-PCRs were
in the linear range of amplification for the target
mRNA, as well as for the control. Each RT-PCR product
was demonstrated on 1.4% agarose gel stained with eth-
idium bromide (Sigma Chemical Co., St. Louis, MO).
The bands were documented, scanned, and quantified
using Quantity One software (PDI, New York, NY) and
normalized with internal control (GAPDH).
Western blot analysis
Cells were lysed in ice-cold lysis buffer (10 mM Tris
(tris (hydroxymethyl) aminomethane, pH 7.5), 0.1 nm
EDTA (Ethylene Diamine Tetraacetic Acid), 0.1 nM EGTA
(Ethylene Glycol Tetraacetic Acid), 0.5% SDS (Sodium
Figure 2 DEX inhibits PTX-induced apoptosis in ovarian cancer SKOV-3 cells. SKOV-3 cells were either left untreated (Con) or treated with
PTX (50 nM) in the absence or presence of DEX (0.1 μM), which was added 24 h prior to PTX treatment. Twenty-four hours after the addition of
PTX, apoptosis rate was measured by PI-staining and then analyzed by FCM. *: p < 0.01 vs. control; *#: p < 0.01 vs. PTX treated cells. Con: control;
PTX: paclitaxel; DEX: dexamethasone.
Figure 1 DEX induces the proliferation of PTX-induced SKOV-3 and HO-8910 cells. SKOV-3 and HO-8910 cells were cultured in a
concentration of 104/mL either in the absence or presence of DEX for 24 h. Then, cells of every concentration of DEX were further incubated with
or without PTX for 48 h, after which proliferation was monitored by MTT assay. Experiments were performed three times. Data were shown as
mean ± SD and compared with DEX 0 nM (Control). *: p < 0.05; **: p < 0.01. PTX: paclitaxel; DEX: dexamethasone.
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Dodecyl Sulfonate), 0.1 mm β-mercaptoethanol, containing
2 μg/mL of each of the protease inhibitors: leupeptin, apro-
tinin, and pepstatin, Sigma Chemical Co., St. Louis, MO)
for 10 min. Protein concentrations in cell lysates were
measured using the Bio-Rad protein determination
assay. Twenty micrograms of protein were separated by
SDS-PAGE, transferred to nitrocellulose membranes
(Schleicher and Schuell, Inc., Burlington, VT), and immu-
noblotted with various primary antibodies. Antibodies to
cleaved caspase-3 and Bcl-XL were obtained from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). The blots were
further incubated with conjugated alkaline phosphatase.
Figure 3 DEX inhibits PTX-induced apoptosis in ovarian cancer HO8910 cells. HO8910 cells were either left untreated (Con) or treated with PTX
(50 nM) in the absence or presence of DEX pre-treatment (0.1 μM). Twenty-four hours following the addition of PTX, apoptosis rate was measured by
annexin V-FITC/PI and then analyzed by FCM. *: p < 0.01 vs. control; *#: p < 0.01 vs. PTX treated cells. Con: control; PTX: paclitaxel; DEX: dexamethasone.
Figure 4 DEX increases the expression of Bcl-XL and survivin but not Bcl-2. SKOV-3 and HO-8910 cells were treated with PTX (50 nM) for 24 h with
or without DEX pre-treatment (0.1 μM). The relative expression levels of Bcl-2, survivin, and Bcl-XL (mRNAs) were determined by semi-quantitative RT-PCR.
A. PCR results of Bcl-2, survivin, and Bcl-XL expression. B. Relative expression levels of Bcl-2, survivin, and Bcl-XL. GAPDH was used as an internal control.
*: p < 0.01 vs. control; *#: p < 0.01 vs. PTX-treated cells. PTX: paclitaxel; DEX: dexamethasone. GAPDH: glyceraldehyde-3-phosphate dehydrogenase.
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Statistical analysis
Statistical analysis was performed using one-way ANOVA
(One-factor Analysis of Variance), with Fisher’s least
significant difference test. Data were expressed as
mean ± SD (Standard Deviation). Differences were consid-
ered significant, if p < 0.05.
Results
DEX promotes PTX-induced proliferation
The effect of DEX on the growth of paclitaxel-induced cells
was firstly examined by MTT assay. As shown in Figure 1,
the growth of PTX-induced SKOV-3 cells and HO-8910
cells was promoted by DEX in a concentration-dependent
manner. These results indicate that DEX can promote the
proliferation of PTX-induced SKOV-3 and HO-8910 cells.
DEX prevents PTX-induced apoptosis
To investigate whether DEX could interfere with apoptosis,
we treated SKOV-3 cells in the presence or absence of
DEX pre-treatment. Twenty-four hours later, apoptosis
was examined by staining of the cells with PI-staining
and then analyzed by FCM. The apoptosis rates in human
ovarian cancer cell line SKOV-3 induced by PTX, were
5.55 ± 0.53% if pre-treated with DEX, and 13.90 ± 1.62% if
not treated with DEX (p (p value) < 0.01) (Figure 2). We
treated HO8910 cells in the presence or absence of DEX
for 24 h as well. The apoptosis was examined by staining
of the cells with annexin V-FITC/PI and then analyzed
by FCM. The percentages of apoptosis in human
ovarian cancer cell line HO-8910 induced by PTX, were
11.45 ± 0.945% if pre-treated with DEX, and 29.94 ± 1.49%
if not treated with DEX (p < 0.01) (Figure 3).
DEX pre-treatment increases the expression of Bcl-XL and
survivin but not Bcl-2 in HO-8910 and SKOV-3 cells
To determine whether anti-apoptotic modulator proteins,
such as survivin, a member of the IAP family, and the Bcl-2
and Bcl-XL proteins of the Bcl-2 family were involved in
DEX-induced apoptosis inhibition, HO-8910 and SKOV-3
cells were treated with PTX (50 nM) for 24 h with or
without DEX pre-treatment (0.1 μM) to examine the
expressions of Bcl-2, Bcl-XL, and survivin. As shown in
Figure 4, the expressions of Bcl-XL and survivin mRNAs
were significantly up-regulated by the pre-treatment of
DEX (p < 0.01), whereas the expression of Bcl-2 was
un-affected (p > 0.05).
The expression of Bcl-XL protein in SKOV-3 and HO-8910 cells
We detected the change of Bcl-XL proteins in SKOV-3
and HO-8910 cells by western blot analysis. As shown in
Figure 5, the expressions of Bcl-XL protein were up-
regulated by DEX pre-treatment in both HO-8910 and
SKOV-3 cells (p < 0.01).
The expressions of cleaved caspase-3 in SKOV-3 and
HO-8910 cells
We detected the change of cleaved caspase-3 proteins in
SKOV-3 and HO-8910 cells by western blot analysis. As
Figure 5 DEX promotes the protein expression of Bcl-XL. SKOV-3 and HO-8910 cells were treated with PTX (50 nM) for 24 h with or without
DEX pre-treatment (0.1 μM). The cells were harvested for detection of Bcl-XL proteins by western blot analysis. β-actin was also detected as a
loading control. A. Western blot product of Bcl-XL protein. B. Relative expression of Bcl-XL protein. *: p < 0.01 vs. control; *#: p < 0.01 vs.
PTX-treated cells. PTX: paclitaxel; DEX: dexamethasone.
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shown in Figure 6, the protein expression of cleaved
caspase-3 was down-regulated by DEX pre-treatment
in both cancer cell lines (p < 0.01).
Discussions
DEX has been introduced to tumor therapy because it
has potent pro-apoptotic effects on lymphoid cells, thus
effective in treating tumor-related edema, inflammation,
pain, and electrolyte imbalances [26]. It can also reduce
nausea, hyperemesis, and acute toxicity in normal tissue
[16,17]. However, more and more data have strongly
recommended that the application of DEX renders the
majority of malignant solid-tumor cells resistant to apop-
tosis and promotes proliferation following cytotoxic therapy
[27,28]. In addition, the anti-chemotherapeutic effect of
DEX can be seen in anticancer drugs such as cisplatin,
5-fluorouracil, adriamycin, actinomycin D, doxorubicin
and gemcitabine [29,30]. It has also been known that
DEX-induced resistance to chemotherapy agents is through
enhancing the anti-apoptotic gene, such as Bcl-XL gene in
glioma cells [31,32] and other solid malignant cells [33-35].
In the present study, we demonstrated that DEX may
protect human ovarian cancer cell lines HO-8910 and
SKOV3 from PTX-induced apoptosis. These findings
suggested that the use of DEX can prevent hypersensitivity
in the therapy of ovarian cancer, but result in resistance
to chemotherapy that reduces tumor growth. Bcl-XL, a
member of the Bcl2 family, is an anti-apoptotic gene on
mitochondria. Several transcription factors are present
in the Bcl-XL promoter region, such as NF-kB, Stat3, Stat5,
and AP-1. DEX has been shown to enhance NF-kB activity
in MCF7 breast cancer cells [36]. In contrast, GCs also
inhibit PTX-induced apoptosis by inhibition of NF-kB
activation [37,38].
Several studies have reported that the inhibitory effect
of DEX on the therapeutic activity of PTX seems to be
apoptosis-specific because PTX-mediated mitotic arrest
or cell cycle distribution was unaffected or marginally
affected by the application of steroid [39-41]. By using
flow cytometry assays, western blot analysis and RT-PCR,
we identified several genes of the death receptor and
anti-apoptotic molecule pathways to be influenced by
DEX. The expression of Bcl-XL and survivin mRNAs were
up-regulated by the pre-treatment of DEX (p < 0.01). How-
ever, the mRNA of Bcl-2 mRNA was un-affected by DEX
pre-treatment (p > 0.05). In term of protein expressions,
Bcl-XL protein was up-regulated by DEX pre-treatment
(p < 0.01). It has been shown, for fibrosarcoma cells, that
glucocorticoids can increase the Bcl-XL level by inducing
the transcriptional activation of the Bcl-XL promoter [42].
Therefore, one might speculate that the inhibitory ef-
fect of DEX on the therapeutic activity of PTX occurs
by increasing the expression of anti-apoptotic genes, such
as Bcl-XL and survivin.
It is well known that caspase −3 is the effector caspase in
apoptosis and can be activated by irradiation, chemothera-
peutics, or members of the tumor necrosis factor family
[43-46]. Therefore, DEX could resist the PTX-induced
expression of key elements of the cell death receptor
pathway, such as cleaved caspase-3, in ovarian cancer.
Figure 6 DEX inhibits the expression of cleaved caspase-3 protein. SKOV-3 and HO-8910 cells were treated with PTX (50 nM) for 24 h with
or without DEX pre-treatment (0.1 μM). Then, cells were harvested for detection of cleaved caspase-3 protein by western blot analysis. β-actin
was also detected as a loading control. A. Western blot product of cleaved caspase-3 protein. B. Relative expression of cleaved caspase-3 protein.
*: p < 0.01 vs. control; *#: p < 0.01 vs. PTX-treated cells. PTX: paclitaxel; DEX: dexamethasone.
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Our further experiment confirmed that the expression
of cleaved caspase-3 was down-regulated by DEX pre-
treatment (p < 0.01). Intriguingly, down-regulation of
these pro-apoptotic genes was not observed in lymphoid
cells. This observation is in line with other reports showing
the up-regulations of pro-apoptotic genes, such as
CD95, caspase-3, and caspase-4, or down-regulations
of anti-apoptotic molecules, such as Bcl-2 and Bcl-XL,
after DEX treatment in lymphoid cells [47-49]. These
pro- and anti-apoptotic effects of DEX might be the
reason for its inhibition of apoptosis in carcinoma cells
but its activation of apoptosis in lymphoid cells.
It is well known that DEX acts through glucocorticoid
receptors (GRs) [50], however, the expressions of GRs were
not evaluated in this study. It is a limitation, because only
with the knowledge of GRs changes, can the effect of DEX
on the cell lines be thoroughly understood.
In conclusion, our data suggested that the application
of DEX significantly inhibited the therapeutic activity of
PTX in ovarian cancer cells. This result is in contrast to
the effect of GCs in lymphoid cells and may involve cell
type–specific regulation of survival molecules or anti-
apoptotic molecules. Thus, our results may provide new
evidence that the anti-apoptotic effect of DEX on human
ovarian cancer cells is mediated by up-regulating Bcl-XL
and surviving, and down-regulating caspase-3 activity.
These findings have profound clinical meanings in
term of proper application of DEX which might reduce
side effects and sacrifice the efficacy of PTX on cancer
cell death as well.
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